BIOREGENX Faces Substantial Doubt on Going Concern, Reports Material Weaknesses & Debt Defaults

summarizeSummary

BIOREGENX's 10-K reveals substantial doubt about its ability to continue as a going concern, citing debt defaults, material weaknesses in internal controls, and declining sales.

check_boxKey Events

• Substantial Doubt on Going Concern

  Management has concluded there is substantial doubt about the company's ability to continue as a going concern due to recurring losses, cash flow deficits, and dependence on external financing.

• Material Weaknesses in Internal Controls

  The company's management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to material weaknesses including an ineffective control environment and inadequate financial statement close processes.

• Significant Debt Defaults

  Notes payable totaling $522,500 are in default, including two Howard Notes and two EIDL loans, indicating severe financial distress.

• Declining Financial Performance

  Net sales decreased by 21% to $1.85 million in 2025 from $2.34 million in 2024, primarily due to product issues with its medical testing machine. The company reported a net loss of $1.54 million in 2025.

auto_awesomeAnalysis

BIOREGENX, INC. has reported significant financial distress and operational challenges in its annual 10-K filing. Management explicitly states 'substantial doubt about the Company's ability to continue as a going concern' due to recurring losses, cash flow deficits, and existing debt defaults. The company's cash on hand is critically low at $69,383, while $522,500 in notes payable are in default. Furthermore, the company disclosed material weaknesses in its internal control over financial reporting, indicating a lack of effective financial oversight and compliance. Sales declined by 21% year-over-year, attributed to product issues with its medical testing machine. These factors collectively paint a grim picture of the company's financial health and operational stability, posing significant risks to investors.